BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and…
BioNTech SE and Kite, a Gilead Company announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing…
Read More...
Read More...
